{"id":"W4386725951","doi":"10.1158/2159-8290.cd-23-0436","title":"Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial","year":2023,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"Pharmacyclics; Genentech; Novocure; Amgen; Aeglea BioTherapeutics; Regeneron Pharmaceuticals; Pfizer; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Oncology; Immune system; Internal medicine; Lung cancer; Clinical endpoint; Surgical oncology; Cancer; Immunotherapy; Clinical trial; Cancer research; Immunology; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007005642,0.0009653193,0.0008412364,0.0001534722,0.0001601065,0.0006805923,0.0004648662,0.0005677241,0.00211219],"category_scores_gemma":[0.0004546543,0.0002606361,0.0006655669,0.0001468782,0.0004875593,0.0005462895,0.00028542,0.001399516,0.0003555299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007762601,"about_ca_system_score_gemma":0.000686664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006523153,"about_ca_topic_score_gemma":0.002595,"domain_scores_codex":[0.9997987,0.0001035288,0.0000113702,0.00003204563,0.00002263676,0.00003176109],"domain_scores_gemma":[0.9997099,0.00004273461,0.00008444049,0.00003209692,0.0000152255,0.0001155488],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7901095,0.02349101,0.00912571,0.000941966,0.002000384,0.0002658291,0.0002038857,0.002462808,0.05627181,0.0004738138,0.005528594,0.1091247],"study_design_scores_gemma":[0.6939511,0.2694813,0.01816538,0.00008128086,0.0008676195,0.0005972863,0.00009377872,0.002262357,0.009644246,0.0003233967,0.004489011,0.00004332045],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958941,0.001641184,0.0001536527,0.0003144558,0.00007622424,0.0003852418,0.0003839334,0.00003108674,0.001120146],"genre_scores_gemma":[0.9938775,0.001249657,0.0007340605,0.0005442491,0.0001023375,0.0005730389,0.001057314,0.00001481937,0.001846971],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00211219,"threshold_uncertainty_score":0.007065952,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06199818663256833,"score_gpt":0.3770023694520501,"score_spread":0.3150041828194818,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}